Symbols / MDXH
MDXH Chart
About
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 182.34M |
| Enterprise Value | 233.61M | Income | -31.43M | Sales | 103.07M |
| Book/sh | -0.17 | Cash/sh | 0.64 | Dividend Yield | — |
| Payout | 0.00% | Employees | 312 | IPO | — |
| P/E | — | Forward P/E | -16.90 | PEG | — |
| P/S | 1.77 | P/B | -21.52 | P/C | — |
| EV/EBITDA | -33.05 | EV/Sales | 2.27 | Quick Ratio | 0.98 |
| Current Ratio | 1.14 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.52 | EPS next Y | -0.21 | EPS Growth | — |
| Revenue Growth | 17.70% | Earnings | 2026-02-26 | ROA | -5.52% |
| ROE | -7.20% | ROIC | — | Gross Margin | 64.48% |
| Oper. Margin | -9.63% | Profit Margin | -30.50% | Shs Outstand | 51.36M |
| Shs Float | 34.34M | Short Float | 0.07% | Short Ratio | 0.19 |
| Short Interest | — | 52W High | 5.33 | 52W Low | 1.35 |
| Beta | -562400.44 | Avg Volume | 124.80K | Volume | 79.50K |
| Target Price | $7.40 | Recom | Strong_buy | Prev Close | $3.61 |
| Price | $3.55 | Change | -1.66% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.40
Mean price target
2. Current target
$3.55
Latest analyst target
3. DCF / Fair value
$-2.12
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.55
Low
$6.00
High
$9.00
Mean
$7.40
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | reit | BTIG | Buy → Buy | $7 |
| 2025-11-13 | main | TD Cowen | Buy → Buy | $7 |
| 2025-11-13 | main | Lake Street | Buy → Buy | $9 |
| 2025-11-13 | main | BTIG | Buy → Buy | $7 |
| 2024-11-07 | main | Piper Sandler | Overweight → Overweight | $6 |
| 2024-10-31 | init | Lake Street | — → Buy | $7 |
| 2024-03-07 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2024-03-07 | main | BTIG | Buy → Buy | $8 |
- Analysts Expect Breakeven For MDxHealth SA (NASDAQ:MDXH) Before Long - simplywall.st Wed, 14 Jan 2026 08
- $15M Precision Diagnostics Deal: MDxHealth Acquires ExoDx Prostate Test Business from Bio-Techne - Stock Titan Mon, 15 Sep 2025 07
- Loss-Making MDxHealth SA (NASDAQ:MDXH) Expected To Breakeven In The Medium-Term - Yahoo Finance hu, 08 Jan 2026 08
- MDXH: BTIG Reiterates Buy Rating with $7 Price Target | MDXH Sto - GuruFocus ue, 23 Dec 2025 08
- MDxHealth reports 23% revenue growth in Q4, issues 2026 guidance - Investing.com Mon, 12 Jan 2026 08
- World’s largest prostate cancer trial adds genomic test to guide care - Stock Titan ue, 06 Jan 2026 08
- MDxHealth SA's (NASDAQ:MDXH) market cap touched US$182m last week, benefiting both individual investors who own 46% as well as institutions - simplywall.st Fri, 28 Nov 2025 08
- Lake Street Maintains MDxHealth(MDXH.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛 ue, 13 Jan 2026 08
- MDxHealth Completes Bio Techne ExoDx Acquisition to Bolster Precision Diagnostics - Yahoo Finance Sun, 21 Sep 2025 07
- Earnings call transcript: MDxHealth Q2 2025 sees revenue growth, stock jumps - Investing.com hu, 14 Aug 2025 07
- MDxHealth Stock: Small-Cap Volatility Meets Big-Cap Expectations - AD HOC NEWS ue, 06 Jan 2026 08
- MDxHealth to Release Q4 and Full Year 2025 Financial Results on February 26, 2026, Followed by Conference Call - Quiver Quantitative hu, 12 Feb 2026 08
- MDxHealth SA (MDXH) Q1 2025: Everything You Need to Know Ahead of Earnings - Yahoo Finance ue, 13 May 2025 07
- MDXH Stock Price and Chart — NASDAQ:MDXH - TradingView Sat, 06 Nov 2021 03
- MDxHealth Completes Reverse Stock Split - Orange County Business Journal Mon, 13 Nov 2023 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -1.43M | -2.22M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.23M | -20.11M | -33.49M | -23.98M |
| TotalUnusualItems | -6.79M | -10.55M | -3.01M | -114.00K |
| TotalUnusualItemsExcludingGoodwill | -6.79M | -10.55M | -3.01M | -114.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.07M | -43.10M | -44.04M | -29.00M |
| ReconciledDepreciation | 8.04M | 6.86M | 4.91M | 3.04M |
| ReconciledCostOfRevenue | 34.16M | 25.52M | 17.58M | 11.40M |
| EBITDA | -22.02M | -30.66M | -36.50M | -24.09M |
| EBIT | -30.06M | -37.52M | -41.41M | -27.13M |
| NetInterestIncome | -6.87M | -5.81M | -2.62M | -1.87M |
| InterestExpense | 7.63M | 5.58M | 2.64M | 1.88M |
| InterestIncome | 1.08M | 1.09M | 125.00K | 11.00K |
| NormalizedIncome | -32.70M | -34.77M | -41.03M | -28.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.07M | -43.10M | -44.04M | -29.00M |
| TotalExpenses | 114.08M | 96.93M | 75.47M | 49.26M |
| TotalOperatingIncomeAsReported | -24.72M | -27.33M | -37.90M | -26.84M |
| DilutedAverageShares | 49.50M | 25.96M | 15.73M | 12.19M |
| BasicAverageShares | 49.50M | 25.96M | 15.73M | 12.19M |
| DilutedEPS | -1.16 | -1.66 | -2.80 | -2.38 |
| BasicEPS | -1.16 | -1.66 | -2.80 | -2.38 |
| DilutedNIAvailtoComStockholders | -38.07M | -43.10M | -44.04M | -29.00M |
| NetIncomeCommonStockholders | -38.07M | -43.10M | -44.04M | -29.00M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -38.07M | -43.10M | -44.04M | -29.00M |
| NetIncomeIncludingNoncontrollingInterests | -38.07M | -43.10M | -44.04M | -29.00M |
| NetIncomeContinuousOperations | -38.07M | -43.10M | -44.04M | -29.00M |
| TaxProvision | 382.00K | 1.00K | 0.00 | 0.00 |
| PretaxIncome | -37.69M | -43.10M | -44.04M | -29.00M |
| OtherIncomeExpense | -6.79M | -10.55M | -3.01M | -114.00K |
| SpecialIncomeCharges | -7.73M | -9.74M | -3.13M | -18.00K |
| OtherSpecialCharges | 3.13M | 1.05M | ||
| RestructuringAndMergernAcquisition | 4.60M | 9.74M | 2.08M | 18.00K |
| GainOnSaleOfSecurity | 941.00K | -806.00K | 116.00K | -96.00K |
| NetNonOperatingInterestIncomeExpense | -6.87M | -5.81M | -2.62M | -1.87M |
| TotalOtherFinanceCost | 317.00K | 1.32M | 107.00K | 7.00K |
| InterestExpenseNonOperating | 7.63M | 5.58M | 2.64M | 1.88M |
| InterestIncomeNonOperating | 1.08M | 1.09M | 125.00K | 11.00K |
| OperatingIncome | -24.03M | -26.74M | -38.41M | -27.02M |
| OperatingExpense | 79.17M | 70.67M | 57.63M | 37.58M |
| OtherOperatingExpenses | -71.00K | -127.00K | -44.00K | -985.00K |
| DepreciationAmortizationDepletionIncomeStatement | 7.29M | 6.12M | 4.65M | 2.76M |
| DepreciationAndAmortizationInIncomeStatement | 7.29M | 6.12M | 4.65M | 2.76M |
| Amortization | 4.91M | 4.49M | 3.17M | 1.61M |
| AmortizationOfIntangiblesIncomeStatement | 4.91M | 4.49M | 3.17M | 1.61M |
| DepreciationIncomeStatement | 2.39M | 1.62M | 1.48M | 1.15M |
| ResearchAndDevelopment | 10.55M | 6.38M | 5.50M | 5.59M |
| SellingGeneralAndAdministration | 61.40M | 58.30M | 47.53M | 30.22M |
| SellingAndMarketingExpense | 6.44M | 7.37M | 4.62M | 3.02M |
| GeneralAndAdministrativeExpense | 54.95M | 50.94M | 42.90M | 27.19M |
| OtherGandA | 9.44M | 12.80M | 14.84M | 4.78M |
| SalariesAndWages | 45.52M | 38.14M | 28.07M | 22.41M |
| GrossProfit | 55.14M | 43.93M | 19.22M | 10.56M |
| CostOfRevenue | 34.91M | 26.26M | 17.84M | 11.68M |
| TotalRevenue | 90.05M | 70.19M | 37.05M | 22.24M |
| OperatingRevenue | 72.33M | 55.72M | 31.15M | 21.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 49.50M | 27.29M | 16.29M | 15.60M |
| ShareIssued | 49.50M | 27.29M | 16.29M | 15.60M |
| NetDebt | 4.49M | 13.83M | 20.03M | |
| TotalDebt | 60.06M | 41.27M | 39.79M | 15.56M |
| TangibleBookValue | -61.68M | -73.06M | -72.78M | 43.45M |
| InvestedCapital | 66.13M | 43.41M | 44.84M | 58.99M |
| WorkingCapital | 24.23M | 18.64M | 10.87M | 50.17M |
| NetTangibleAssets | -61.68M | -73.06M | -72.78M | 43.45M |
| CapitalLeaseObligations | 8.77M | 5.06M | 4.26M | 3.46M |
| CommonStockEquity | 14.84M | 7.21M | 9.31M | 46.90M |
| TotalCapitalization | 65.81M | 42.77M | 44.23M | 54.55M |
| TotalEquityGrossMinorityInterest | 14.84M | 7.21M | 9.31M | 46.90M |
| StockholdersEquity | 14.84M | 7.21M | 9.31M | 46.90M |
| OtherEquityInterest | 17.12M | 12.14M | 11.47M | 10.61M |
| GainsLossesNotAffectingRetainedEarnings | -615.00K | -593.00K | -444.00K | -1.04M |
| ForeignCurrencyTranslationAdjustments | -615.00K | -593.00K | -444.00K | -1.04M |
| RetainedEarnings | -369.51M | -331.45M | -288.35M | -244.30M |
| AdditionalPaidInCapital | 153.18M | 153.18M | 153.18M | 153.18M |
| CapitalStock | 214.67M | 173.93M | 133.45M | 128.45M |
| CommonStock | 214.67M | 173.93M | 133.45M | 128.45M |
| TotalLiabilitiesNetMinorityInterest | 142.49M | 121.92M | 109.82M | 28.17M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 99.83M | 102.40M | 91.54M | 11.74M |
| OtherNonCurrentLiabilities | 41.45M | 63.26M | 53.54M | 1.47M |
| LongTermDebtAndCapitalLeaseObligation | 58.38M | 39.14M | 38.01M | 10.28M |
| LongTermCapitalLeaseObligation | 7.41M | 3.58M | 3.09M | 2.62M |
| LongTermDebt | 50.97M | 35.56M | 34.91M | 7.65M |
| CurrentLiabilities | 42.66M | 19.52M | 18.28M | 16.43M |
| OtherCurrentLiabilities | 26.41M | 2.90M | 2.33M | 961.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.68M | 2.12M | 1.79M | 5.28M |
| CurrentCapitalLeaseObligation | 1.36M | 1.48M | 1.17M | 840.00K |
| CurrentDebt | 324.00K | 643.00K | 616.00K | 4.44M |
| OtherCurrentBorrowings | 324.00K | 643.00K | 616.00K | 4.44M |
| PayablesAndAccruedExpenses | 14.57M | 14.51M | 14.16M | 10.19M |
| CurrentAccruedExpenses | 6.57M | 5.69M | 3.98M | 2.73M |
| Payables | 8.00M | 8.81M | 10.18M | 7.46M |
| AccountsPayable | 8.00M | 8.81M | 10.18M | 7.46M |
| TotalAssets | 157.33M | 129.13M | 119.14M | 75.07M |
| TotalNonCurrentAssets | 90.43M | 90.97M | 89.99M | 8.47M |
| OtherNonCurrentAssets | -1.00K | |||
| InvestmentsAndAdvances | 936.00K | 763.00K | 0.00 | |
| InvestmentinFinancialAssets | 936.00K | 763.00K | 0.00 | |
| AvailableForSaleSecurities | 936.00K | 763.00K | ||
| GoodwillAndOtherIntangibleAssets | 76.52M | 80.26M | 82.09M | 3.45M |
| OtherIntangibleAssets | 40.59M | 44.34M | 46.17M | 3.45M |
| Goodwill | 35.93M | 35.93M | 35.93M | 0.00 |
| NetPPE | 12.98M | 9.95M | 7.89M | 5.02M |
| AccumulatedDepreciation | -10.27M | -12.83M | -10.66M | -9.10M |
| GrossPPE | 23.25M | 22.78M | 18.55M | 14.11M |
| Leases | 2.63M | 2.80M | 2.06M | 1.34M |
| OtherProperties | 9.59M | 10.79M | 8.30M | 6.18M |
| MachineryFurnitureEquipment | 1.73M | 1.91M | 1.63M | 1.46M |
| BuildingsAndImprovements | 9.31M | 7.29M | 6.57M | 5.13M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 66.89M | 38.16M | 29.15M | 66.61M |
| OtherCurrentAssets | 36.00K | 23.00K | ||
| PrepaidAssets | 1.70M | 1.70M | 1.81M | 1.11M |
| Inventory | 3.87M | 2.78M | 2.33M | 1.91M |
| RawMaterials | 3.87M | 2.78M | 2.33M | 1.91M |
| Receivables | 14.53M | 11.27M | 9.51M | 5.06M |
| OtherReceivables | 54.00K | 235.00K | ||
| TaxesReceivable | 92.00K | 183.00K | 97.00K | 246.00K |
| AccountsReceivable | 14.44M | 11.09M | 9.36M | 4.58M |
| CashCashEquivalentsAndShortTermInvestments | 46.80M | 22.38M | 15.50M | 58.50M |
| CashAndCashEquivalents | 46.80M | 22.38M | 15.50M | 58.50M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.69M | -26.52M | -38.28M | -23.44M |
| RepaymentOfDebt | -41.42M | -3.27M | -12.16M | -1.06M |
| IssuanceOfDebt | 53.01M | 0.00 | 34.29M | 0.00 |
| IssuanceOfCapitalStock | 40.74M | 39.60M | 0.00 | 68.57M |
| CapitalExpenditure | -2.16M | -5.02M | -4.16M | -896.00K |
| EndCashPosition | 46.80M | 22.38M | 15.50M | 58.50M |
| BeginningCashPosition | 22.38M | 15.50M | 58.50M | 15.95M |
| EffectOfExchangeRateChanges | -14.00K | 25.00K | -555.00K | -520.00K |
| ChangesInCash | 24.43M | 6.85M | -42.44M | 43.06M |
| FinancingCashFlow | 44.60M | 32.28M | 20.72M | 66.50M |
| CashFlowFromContinuingFinancingActivities | 44.60M | 32.28M | 20.72M | 66.50M |
| NetOtherFinancingCharges | -1.03M | -440.00K | 125.00K | 11.00K |
| InterestPaidCFF | -6.70M | -3.61M | -1.41M | -1.01M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 40.74M | 39.60M | 0.00 | 68.57M |
| CommonStockIssuance | 40.74M | 39.60M | 0.00 | 68.57M |
| NetIssuancePaymentsOfDebt | 11.59M | -3.27M | 22.13M | -1.06M |
| NetLongTermDebtIssuance | 11.59M | -3.27M | 22.13M | -1.06M |
| LongTermDebtPayments | -41.42M | -3.27M | -12.16M | -1.06M |
| LongTermDebtIssuance | 53.01M | 0.00 | 34.29M | 0.00 |
| InvestingCashFlow | -1.64M | -3.93M | -29.04M | -885.00K |
| CashFlowFromContinuingInvestingActivities | -1.64M | -3.93M | -29.04M | -885.00K |
| NetOtherInvestingChanges | -555.00K | |||
| InterestReceivedCFI | 1.08M | 1.09M | 125.00K | 11.00K |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -25.00M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -25.00M | 0.00 |
| NetIntangiblesPurchaseAndSale | -971.00K | -2.27M | -1.37M | 0.00 |
| PurchaseOfIntangibles | -971.00K | -2.27M | -1.37M | 0.00 |
| NetPPEPurchaseAndSale | -1.19M | -2.75M | -2.79M | -896.00K |
| PurchaseOfPPE | -1.19M | -2.75M | -2.79M | -896.00K |
| OperatingCashFlow | -18.53M | -21.50M | -34.12M | -22.55M |
| CashFlowFromContinuingOperatingActivities | -18.53M | -21.50M | -34.12M | -22.55M |
| ChangeInWorkingCapital | -3.86M | -2.12M | -1.56M | 360.00K |
| ChangeInPayablesAndAccruedExpense | 458.00K | 20.00K | 3.97M | 1.33M |
| ChangeInPayable | 458.00K | 20.00K | 3.97M | 1.33M |
| ChangeInInventory | -1.09M | -452.00K | -416.00K | 413.00K |
| ChangeInReceivables | -3.23M | -1.68M | -5.12M | -1.38M |
| OtherNonCashItems | 286.00K | 421.00K | -473.00K | -325.00K |
| StockBasedCompensation | 1.73M | 665.00K | 867.00K | 1.22M |
| AssetImpairmentCharge | 0.00 | 0.00 | 44.00K | 0.00 |
| DepreciationAmortizationDepletion | 8.04M | 6.86M | 4.91M | 3.04M |
| DepreciationAndAmortization | 8.04M | 6.86M | 4.91M | 3.04M |
| AmortizationCashFlow | 4.91M | 4.49M | 3.17M | 1.61M |
| AmortizationOfIntangibles | 4.91M | 4.49M | 3.17M | 1.61M |
| Depreciation | 3.13M | 2.37M | 1.74M | 1.43M |
| NetIncomeFromContinuingOperations | -24.72M | -27.33M | -37.90M | -26.84M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42023-02-28 View
Public Trades for MDXH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|